(ASH) Ashland Global Holdings - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 2.504m USD | Total Return: 17.8% in 12m
Avg Turnover: 55.6M
EPS Trend: -55.9%
Qual. Beats: 0
Rev. Trend: -97.2%
Qual. Beats: 0
Warnings
Choppy
Tailwinds
No distinct edge detected
Ashland Inc. (NYSE: ASH) is a global provider of additives and specialty ingredients, operating across four primary segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The company serves diverse end markets including pharmaceuticals, nutrition, agriculture, construction, and energy. Its portfolio focuses on functional chemistries such as cellulose ethers and bio-based polymers used to enhance the performance of consumer and industrial products.
The specialty chemicals sector is characterized by high barriers to entry due to complex formulation requirements and rigorous regulatory standards in the pharmaceutical and personal care industries. Ashland’s business model relies on a pull-through strategy where proprietary ingredients are integrated into customers final product formulations, often leading to long-term supply relationships and sticky revenue streams.
Investors can evaluate the companys valuation metrics and growth trajectory further on ValueRay.
Founded in 1924 and headquartered in Wilmington, Delaware, the firm rebranded from Ashland Global Holdings Inc. to Ashland Inc. in 2022 to reflect its streamlined focus on high-margin specialty additives. Its global infrastructure spans North America, Europe, and Asia Pacific, positioning it to capture demand in both established and emerging markets.
- Pharmaceutical demand for controlled release polymers drives Life Sciences segment revenue
- Raw material cost fluctuations for butanediol impact Intermediates segment profit margins
- Global architectural coatings demand dictates volume for the Specialty Additives business
- Consumer shift toward biodegradable personal care ingredients influences product mix margins
- High exposure to European and Asian industrial cycles affects consolidated organic growth
| Net Income: -706.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 6.79 > 1.0 |
| NWC/Revenue: 45.00% < 20% (prev 31.38%; Δ 13.61% < -1%) |
| CFO/TA 0.09 > 3% & CFO 405.0m > Net Income -706.0m |
| Net Debt (1.24b) to EBITDA (368.0m): 3.37 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.0m) vs 12m ago -2.13% < -2% |
| Gross Margin: 25.21% > 18% (prev 0.31%; Δ 2.49k% > 0.5%) |
| Asset Turnover: 37.18% > 50% (prev 37.26%; Δ -0.09% > 0%) |
| Interest Coverage Ratio: 1.41 > 6 (EBITDA TTM 368.0m / Interest Expense TTM 66.0m) |
| A: 0.18 (Total Current Assets 1.21b - Total Current Liabilities 395.0m) / Total Assets 4.50b |
| B: 0.50 (Retained Earnings 2.26b / Total Assets 4.50b) |
| C: 0.02 (EBIT TTM 93.0m / Avg Total Assets 4.87b) |
| D: 0.71 (Book Value of Equity 1.87b / Total Liabilities 2.63b) |
| Altman-Z'' = 3.70 = AA |
| DSRI: 1.16 (Receivables 244.0m/226.0m, Revenue 1.81b/1.95b) |
| GMI: 1.22 (GM 25.21% / 30.82%) |
| AQI: 0.83 (AQ_t 0.45 / AQ_t-1 0.54) |
| SGI: 0.93 (Revenue 1.81b / 1.95b) |
| TATA: -0.25 (NI -706.0m - CFO 405.0m) / TA 4.50b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 57.21 with a total of 418,631 shares traded.
Over the past week, the price has changed by +4.97%,
over one month by +0.79%,
over three months by -8.64% and
over the past year by +17.82%.
Ashland Global Holdings has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy ASH.
- StrongBuy: 6
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 64 | 11.9% |
P/S = 1.3848
P/B = 1.3498
P/EG = 1.226
Revenue TTM = 1.81b USD
EBIT TTM = 93.0m USD
EBITDA TTM = 368.0m USD
Long Term Debt = 1.37b USD (from longTermDebt, last quarter)
Short Term Debt = 19.0m USD (from shortTermDebt, last quarter)
Debt = 1.58b USD (from shortLongTermDebtTotal, last quarter) + Leases 104.0m
Net Debt = 1.24b USD (calculated: Debt 1.58b - CCE 343.0m)
Enterprise Value = 3.74b USD (2.50b + Debt 1.58b - CCE 343.0m)
Interest Coverage Ratio = 1.41 (Ebit TTM 93.0m / Interest Expense TTM 66.0m)
EV/FCF = 11.21x (Enterprise Value 3.74b / FCF TTM 334.0m)
FCF Yield = 8.92% (FCF TTM 334.0m / Enterprise Value 3.74b)
FCF Margin = 18.46% (FCF TTM 334.0m / Revenue TTM 1.81b)
Net Margin = -39.03% (Net Income TTM -706.0m / Revenue TTM 1.81b)
Gross Margin = 25.21% ((Revenue TTM 1.81b - Cost of Revenue TTM 1.35b) / Revenue TTM)
Gross Margin QoQ = 30.50% (prev 20.73%)
Tobins Q-Ratio = 0.83 (Enterprise Value 3.74b / Total Assets 4.50b)
Interest Expense / Debt = 4.17% (Interest Expense 66.0m / Debt 1.58b)
Taxrate = 25.0% (5.00m / 20.0m)
NOPAT = 69.8m (EBIT 93.0m * (1 - 25.00%))
Current Ratio = 3.06 (Total Current Assets 1.21b / Total Current Liabilities 395.0m)
Debt / Equity = 0.85 (Debt 1.58b / totalStockholderEquity, last quarter 1.87b)
Debt / EBITDA = 3.37 (Net Debt 1.24b / EBITDA 368.0m)
Debt / FCF = 3.71 (Net Debt 1.24b / FCF TTM 334.0m)
Total Stockholder Equity = 1.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.51% (Net Income -706.0m / Total Assets 4.50b)
RoE = -37.54% (Net Income TTM -706.0m / Total Stockholder Equity 1.88b)
RoCE = 2.86% (EBIT 93.0m / Capital Employed (Equity 1.88b + L.T.Debt 1.37b))
RoIC = 1.78% (NOPAT 69.8m / Invested Capital 3.92b)
WACC = 7.47% (E(2.50b)/V(4.09b) * Re(10.21%) + D(1.58b)/V(4.09b) * Rd(4.17%) * (1-Tc(0.25)))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.19 | Cagr: -4.48%
[DCF] Terminal Value 77.97% ; FCFF base≈213.6m ; Y1≈244.9m ; Y5≈360.4m
[DCF] Fair Price = 91.38 (EV 5.42b - Net Debt 1.24b = Equity 4.18b / Shares 45.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -55.88 | EPS CAGR: -8.20% | SUE: -0.22 | # QB: 0
Revenue Correlation: -97.21 | Revenue CAGR: -8.56% | SUE: -0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.10 | Chg30d=-10.30% | Revisions=-50% | Analysts=9
EPS current Year (2026-09-30): EPS=3.62 | Chg30d=-7.09% | Revisions=-71% | GrowthEPS=+7.2% | GrowthRev=+1.4%
EPS next Year (2027-09-30): EPS=4.38 | Chg30d=-7.71% | Revisions=-69% | GrowthEPS=+20.9% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: -71%